Want to see CH:PPGN full AI Analyst Report?
Top Page
PolyPeptide Group AG
(PPGN)
Select Model
Select Model
Rating:56Neutral
Price Target:
CHF45.00
▲(2.39% Upside)
Action:Reiterated
Date:07/04/26
The score is held back mainly by weak financial performance (continued net losses and volatile free cash flow) and unattractive earnings-based valuation (negative P/E). These are partly offset by strong technical momentum with price well above key moving averages, though overbought indicators add near-term risk.
Positive Factors
Integrated CDMO Model
Coverage across development, analytical, regulatory-supporting and commercial manufacturing services can deepen customer relationships and support program progression. This lifecycle model creates opportunities for repeat work as successful drug programs advance from clinical development into recurring commercial supply.
Negative Factors
Persistent Net Losses
Several years of net losses and materially compressed margins show that revenue growth has not yet translated into dependable profitability. The weak earnings profile may restrict internally funded investment and leaves future performance dependent on successful margin recovery rather than growth alone.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated CDMO Model
Coverage across development, analytical, regulatory-supporting and commercial manufacturing services can deepen customer relationships and support program progression. This lifecycle model creates opportunities for repeat work as successful drug programs advance from clinical development into recurring commercial supply.
Read all positive factors
PolyPeptide Group AG (PPGN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.45B
Dividend Yield0.35%
Average Volume (3M)130.17K
Price to Earnings (P/E)108.4
Beta (1Y)1.17
Revenue Growth22.06%
EPS GrowthN/A
CountryCH
Employees1,460
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.43
Shares Outstanding33,125,000
10 Day Avg. Volume86,070
30 Day Avg. Volume130,170
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF44.10Price Target Upside0.35% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.86
Revenue Forecast (FY)CHF496.10M
PolyPeptide Group AG Business Overview & Revenue Model
Company Description
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic f...
How the Company Makes Money
PolyPeptide Group makes money primarily by providing fee-based CDMO services to pharmaceutical and biotech customers that outsource the development and manufacture of peptide (and, more recently, oligonucleotide) APIs. Its core revenue stream is c...
PolyPeptide Group AG Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
51
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 458.84M | 391.87M | 338.69M | 320.37M | 280.98M | 282.13M |
| Gross Profit | 103.61M | 64.32M | 39.27M | 4.77M | 51.99M | 99.70M |
| EBITDA | 79.02M | 44.42M | 28.42M | -22.15M | 35.72M | 83.35M |
| Net Income | 14.45M | -21.31M | -19.56M | -51.44M | 7.77M | 47.26M |
Balance Sheet | ||||||
| Total Assets | 863.45M | 825.31M | 756.58M | 689.09M | 575.78M | 595.04M |
| Cash, Cash Equivalents and Short-Term Investments | 59.21M | 74.53M | 68.28M | 95.71M | 37.53M | 136.30M |
| Total Debt | 139.52M | 130.46M | 94.12M | 113.66M | 21.22M | 18.00M |
| Total Liabilities | 511.14M | 484.98M | 399.33M | 307.86M | 154.10M | 173.87M |
| Stockholders Equity | 352.31M | 340.33M | 357.24M | 381.23M | 421.68M | 421.17M |
Cash Flow | ||||||
| Free Cash Flow | -49.75M | -30.44M | 2.43M | -20.25M | -69.64M | -16.61M |
| Operating Cash Flow | 52.60M | 78.02M | 89.40M | 36.48M | 5.46M | 57.35M |
| Investing Cash Flow | -106.28M | -112.44M | -91.02M | -59.51M | -78.44M | -80.84M |
| Financing Cash Flow | 33.77M | 34.01M | -25.32M | 84.55M | -26.87M | 130.93M |
PolyPeptide Group AG Technical Analysis
Neutral
43.95
Price Trends
44.09
Negative
42.01
Positive
34.82
Positive
Market Momentum
0.03
Positive
50.57
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:PPGN, the sentiment is Neutral. The current price of 43.95 is below the 20-day moving average (MA) of 44.00, below the 50-day MA of 44.09, and above the 200-day MA of 34.82, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:PPGN.
PolyPeptide Group AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | CHF5.89B | 39.47 | 10.27% | 1.15% | 4.51% | 11.05% | |
67 Neutral | CHF3.30B | 18.71 | 16.14% | 0.55% | 3.64% | 10.93% | |
66 Neutral | CHF37.18B | -354.29 | ― | 0.92% | -10.77% | -114.77% | |
62 Neutral | CHF30.19B | 55.25 | 7.04% | 1.17% | 0.81% | 165.32% | |
56 Neutral | CHF1.45B | 108.43 | ― | 0.35% | 22.06% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
CH:PPGN
PolyPeptide Group AG
44.00
18.40
71.87%
CH:LONN
Lonza Group Ltd
545.60
10.41
1.95%
CH:BANB
Bachem Holding AG
78.55
14.38
22.40%
CH:SFZN
Siegfried Holding AG
73.15
-10.02
-12.05%
CH:SDZ
Sandoz Group Ltd
68.62
21.06
44.28%
CH:JCARE
Joincare Pharmaceutical Group Industry Co., Ltd. Sponsored GDR Class A RegS
8.00
2.91
57.02%
PolyPeptide Group AG Corporate Events
Samsung Peptide Launches CHF 1.46 Billion Tender Offer for PolyPeptide
Aug 31, 2026
Samsung Peptide AG, a subsidiary of Samsung Biologics, has published the offer prospectus for a public tender offer to acquire all publicly held shares of PolyPeptide Group AG at CHF 44.31 per share in cash, valuing the Swiss peptide CDMO at about...
PolyPeptide lifts 2026 outlook after strong H1 surge in peptide demand
Aug 13, 2026
PolyPeptide Group reported a 41.6% year-on-year jump in first-half 2026 revenue to €236.6 million, driven chiefly by a 72.7% surge in sales from metabolic therapeutics and strong utilization of new large-scale capacity in Belgium. EBITDA cli...
Samsung Biologics Moves to Acquire Fast‑Growing Peptide CDMO PolyPeptide
Jul 20, 2026
PolyPeptide Group AG, a specialist in peptide‑based active pharmaceutical ingredients, reported strong operational momentum in the first half of 2026, underpinned by surging demand in metabolic therapeutics. The company’s growing expos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.